These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 26049681)

  • 1. Improvement in Visual Fields After Treatment of Intracranial Meningioma With Bevacizumab.
    Ly KI; Hamilton SR; Rostomily RC; Rockhill JK; Mrugala MM
    J Neuroophthalmol; 2015 Dec; 35(4):382-6. PubMed ID: 26049681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series.
    Lou E; Sumrall AL; Turner S; Peters KB; Desjardins A; Vredenburgh JJ; McLendon RE; Herndon JE; McSherry F; Norfleet J; Friedman HS; Reardon DA
    J Neurooncol; 2012 Aug; 109(1):63-70. PubMed ID: 22535433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bevacizumab in refractory higher-grade and atypical meningioma: the current state of affairs.
    Dasanu CA; Alvarez-Argote J; Limonadi FM; Codreanu I
    Expert Opin Biol Ther; 2019 Feb; 19(2):99-104. PubMed ID: 30556741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea.
    Schrell UM; Rittig MG; Anders M; Koch UH; Marschalek R; Kiesewetter F; Fahlbusch R
    J Neurosurg; 1997 May; 86(5):840-4. PubMed ID: 9126900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The controversial role of Bevacizumab in the treatment of patients with intracranial meningioma: a comprehensive literature review.
    Scerrati A; Mongardi L; Visani J; Lofrese G; Cavallo MA; Fiorentino A; De Bonis P
    Expert Rev Anticancer Ther; 2020 Mar; 20(3):197-203. PubMed ID: 32116057
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of bevacizumab on intracranial meningiomas in patients with neurofibromatosis type 2 - a retrospective case series.
    Alanin MC; Klausen C; Caye-Thomasen P; Thomsen C; Fugleholm K; Poulsgaard L; Lassen U; Mau-Sorensen M; Hofland KF
    Int J Neurosci; 2016 Nov; 126(11):1002-6. PubMed ID: 26365467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atypical and anaplastic meningiomas treated with bevacizumab.
    Nayak L; Iwamoto FM; Rudnick JD; Norden AD; Lee EQ; Drappatz J; Omuro A; Kaley TJ
    J Neurooncol; 2012 Aug; 109(1):187-93. PubMed ID: 22544653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intratumoral and peritumoral post-irradiation changes, but not viable tumor tissue, may respond to bevacizumab in previously irradiated meningiomas.
    Furuse M; Nonoguchi N; Kawabata S; Miyata T; Toho T; Kuroiwa T; Miyatake S
    Radiat Oncol; 2015 Jul; 10():156. PubMed ID: 26223253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bevacizumab treatment for vestibular schwannoma in a patient with neurofibromatosis type 2: hearing improvement and tumor shrinkage.
    Sponghini AP; Platini F; Rondonotti D; Soffietti R
    Tumori; 2015 Nov; 101(6):e167-70. PubMed ID: 26108240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinetics of tumor size and peritumoral brain edema before, during, and after systemic therapy in recurrent WHO grade II or III meningioma.
    Furtner J; Schöpf V; Seystahl K; Le Rhun E; Rudà R; Roelcke U; Koeppen S; Berghoff AS; Marosi C; Clement P; Faedi M; Watts C; Wick W; Soffietti R; Weller M; Preusser M
    Neuro Oncol; 2016 Mar; 18(3):401-7. PubMed ID: 26354929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regression of a meningioma during paclitaxel and bevacizumab therapy for breast cancer.
    Wilson TJ; Heth JA
    J Clin Neurosci; 2012 Mar; 19(3):468-9. PubMed ID: 22245272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intracranial meningiomas, the VEGF-A pathway, and peritumoral brain oedema.
    Nassehi D
    Dan Med J; 2013 Apr; 60(4):B4626. PubMed ID: 23651727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determinants of postoperative visual recovery in suprasellar meningiomas.
    Galal A; Faisal A; Al-Werdany M; El Shehaby A; Lotfy T; Moharram H
    Acta Neurochir (Wien); 2010 Jan; 152(1):69-77. PubMed ID: 19707716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II trial of bevacizumab and everolimus as treatment for patients with refractory, progressive intracranial meningioma.
    Shih KC; Chowdhary S; Rosenblatt P; Weir AB; Shepard GC; Williams JT; Shastry M; Burris HA; Hainsworth JD
    J Neurooncol; 2016 Sep; 129(2):281-8. PubMed ID: 27311730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon-alpha for recurrent World Health Organization grade 1 intracranial meningiomas.
    Chamberlain MC; Glantz MJ
    Cancer; 2008 Oct; 113(8):2146-51. PubMed ID: 18756531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic therapy for relapsed/refractory meningioma: Is there potential for antiangiogenic agents?
    Dasanu CA; Samara Y; Codreanu I; Limonadi FM; Hamid O; Alvarez-Argote J
    J Oncol Pharm Pract; 2019 Apr; 25(3):638-647. PubMed ID: 30253729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bevacizumab treatment for meningiomas in NF2: a retrospective analysis of 15 patients.
    Nunes FP; Merker VL; Jennings D; Caruso PA; di Tomaso E; Muzikansky A; Barker FG; Stemmer-Rachamimov A; Plotkin SR
    PLoS One; 2013; 8(3):e59941. PubMed ID: 23555840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clear cell meningioma presenting as rapidly deteriorating visual field and acuity during pregnancy.
    Baxter DS; Smith P; Stewart K; Murphy M
    J Clin Neurosci; 2009 Nov; 16(11):1502-4. PubMed ID: 19632846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug review: Safety and efficacy of bevacizumab for glioblastoma and other brain tumors.
    Narita Y
    Jpn J Clin Oncol; 2013 Jun; 43(6):587-95. PubMed ID: 23585688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stereotactic radiation treatment for recurrent nonbenign meningiomas.
    Mattozo CA; De Salles AA; Klement IA; Gorgulho A; McArthur D; Ford JM; Agazaryan N; Kelly DF; Selch MT
    J Neurosurg; 2007 May; 106(5):846-54. PubMed ID: 17542529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.